Insmed reported $-151475000 in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acelrx Pharmaceuticals ACRX:US USD -6632000 6.94M
Alimera Sciences ALIM:US USD -3411000 1.44M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Cytokinetics CYTK:US USD -127030000 3.66M
Dynavax Technologies DVAX:US USD 63.14M 1.74M
Gilead Sciences GILD:US USD 2.27B 570M
Heron Therapeutics HRTX:US USD -20355000 21.53M
Insmed INSM:US USD -151475000 23.78M
Mirati Therapeutics MRTX:US USD -211723000 25.28M
Novartis NVS:US USD 1.95B 219M
Regeneron Pharmaceuticals REGN:US USD 1.15B 76.9M
Sarepta Therapeutics SRPT:US USD -109408000 147.39M
Seattle Genetics SGEN:US USD -154004000 38.8M
Ultragenyx Pharmaceutical RARE:US USD -145628000 79.44M
Vertex Pharmaceuticals VRTX:US USD 1.03B 93.2M